EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming

Remi Adelaiye-Ogala, Justin Budka, Nur P. Damayanti, Justine Arrington, Mary Ferris, Chuan Chih Hsu, Sreenivasulu Chintala, Ashley Orillion, Kiersten Marie Miles, Li Shen, May Elbanna, Eric Ciamporcero, Sreevani Arisa, Piergiorgio Pettazzoni, Giulio F. Draetta, Mukund Seshadri, Bradley Hancock, Milan Radovich, Janaiah Kota, Michael BuckHeike Keilhack, Brian P. McCarthy, Scott A. Persohn, Paul Territo, Yong Zang, Joseph Irudayaraj, W. Andy Tao, Peter Hollenhorst, Roberto Pili

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC). Recent reports suggest that drug resistance is driven by tumor adaptation via epigenetic mechanisms that activate alternative survival pathways. The histone methyl transferase EZH2 is frequently altered in many cancers, including ccRCC. To evaluate its role in ccRCC resistance to RTKi, we established and characterized a spontaneously metastatic, patient-derived xenograft model that is intrinsically resistant to the RTKi sunitinib, but not to the VEGF therapeutic antibody bevacizumab. Sunitinib maintained its antiangiogenic and antimetastatic activity but lost its direct antitumor effects due to kinome reprogramming, which resulted in suppression of proapoptotic and cell-cycle–regulatory target genes. Modulating EZH2 expression or activity suppressed phosphorylation of certain RTKs, restoring the antitumor effects of sunitinib in models of acquired or intrinsically resistant ccRCC. Overall, our results highlight EZH2 as a rational target for therapeutic intervention in sunitinib-resistant ccRCC as well as a predictive marker for RTKi response in this disease.

Original languageEnglish (US)
Pages (from-to)6651-6666
Number of pages16
JournalCancer Research
Volume77
Issue number23
DOIs
StatePublished - Dec 1 2017

Fingerprint

Renal Cell Carcinoma
Receptor Protein-Tyrosine Kinases
Transferases
Drug Resistance
Heterografts
Epigenomics
Histones
Vascular Endothelial Growth Factor A
Neoplasms
Phosphorylation
sunitinib
Survival
Antibodies
Therapeutics
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adelaiye-Ogala, R., Budka, J., Damayanti, N. P., Arrington, J., Ferris, M., Hsu, C. C., ... Pili, R. (2017). EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming. Cancer Research, 77(23), 6651-6666. https://doi.org/10.1158/0008-5472.CAN-17-0899

EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming. / Adelaiye-Ogala, Remi; Budka, Justin; Damayanti, Nur P.; Arrington, Justine; Ferris, Mary; Hsu, Chuan Chih; Chintala, Sreenivasulu; Orillion, Ashley; Miles, Kiersten Marie; Shen, Li; Elbanna, May; Ciamporcero, Eric; Arisa, Sreevani; Pettazzoni, Piergiorgio; Draetta, Giulio F.; Seshadri, Mukund; Hancock, Bradley; Radovich, Milan; Kota, Janaiah; Buck, Michael; Keilhack, Heike; McCarthy, Brian P.; Persohn, Scott A.; Territo, Paul; Zang, Yong; Irudayaraj, Joseph; Tao, W. Andy; Hollenhorst, Peter; Pili, Roberto.

In: Cancer Research, Vol. 77, No. 23, 01.12.2017, p. 6651-6666.

Research output: Contribution to journalArticle

Adelaiye-Ogala, R, Budka, J, Damayanti, NP, Arrington, J, Ferris, M, Hsu, CC, Chintala, S, Orillion, A, Miles, KM, Shen, L, Elbanna, M, Ciamporcero, E, Arisa, S, Pettazzoni, P, Draetta, GF, Seshadri, M, Hancock, B, Radovich, M, Kota, J, Buck, M, Keilhack, H, McCarthy, BP, Persohn, SA, Territo, P, Zang, Y, Irudayaraj, J, Tao, WA, Hollenhorst, P & Pili, R 2017, 'EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming', Cancer Research, vol. 77, no. 23, pp. 6651-6666. https://doi.org/10.1158/0008-5472.CAN-17-0899
Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC et al. EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming. Cancer Research. 2017 Dec 1;77(23):6651-6666. https://doi.org/10.1158/0008-5472.CAN-17-0899
Adelaiye-Ogala, Remi ; Budka, Justin ; Damayanti, Nur P. ; Arrington, Justine ; Ferris, Mary ; Hsu, Chuan Chih ; Chintala, Sreenivasulu ; Orillion, Ashley ; Miles, Kiersten Marie ; Shen, Li ; Elbanna, May ; Ciamporcero, Eric ; Arisa, Sreevani ; Pettazzoni, Piergiorgio ; Draetta, Giulio F. ; Seshadri, Mukund ; Hancock, Bradley ; Radovich, Milan ; Kota, Janaiah ; Buck, Michael ; Keilhack, Heike ; McCarthy, Brian P. ; Persohn, Scott A. ; Territo, Paul ; Zang, Yong ; Irudayaraj, Joseph ; Tao, W. Andy ; Hollenhorst, Peter ; Pili, Roberto. / EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming. In: Cancer Research. 2017 ; Vol. 77, No. 23. pp. 6651-6666.
@article{78e297cd626e4ef1ae50a1e32044ac34,
title = "EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming",
abstract = "Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC). Recent reports suggest that drug resistance is driven by tumor adaptation via epigenetic mechanisms that activate alternative survival pathways. The histone methyl transferase EZH2 is frequently altered in many cancers, including ccRCC. To evaluate its role in ccRCC resistance to RTKi, we established and characterized a spontaneously metastatic, patient-derived xenograft model that is intrinsically resistant to the RTKi sunitinib, but not to the VEGF therapeutic antibody bevacizumab. Sunitinib maintained its antiangiogenic and antimetastatic activity but lost its direct antitumor effects due to kinome reprogramming, which resulted in suppression of proapoptotic and cell-cycle–regulatory target genes. Modulating EZH2 expression or activity suppressed phosphorylation of certain RTKs, restoring the antitumor effects of sunitinib in models of acquired or intrinsically resistant ccRCC. Overall, our results highlight EZH2 as a rational target for therapeutic intervention in sunitinib-resistant ccRCC as well as a predictive marker for RTKi response in this disease.",
author = "Remi Adelaiye-Ogala and Justin Budka and Damayanti, {Nur P.} and Justine Arrington and Mary Ferris and Hsu, {Chuan Chih} and Sreenivasulu Chintala and Ashley Orillion and Miles, {Kiersten Marie} and Li Shen and May Elbanna and Eric Ciamporcero and Sreevani Arisa and Piergiorgio Pettazzoni and Draetta, {Giulio F.} and Mukund Seshadri and Bradley Hancock and Milan Radovich and Janaiah Kota and Michael Buck and Heike Keilhack and McCarthy, {Brian P.} and Persohn, {Scott A.} and Paul Territo and Yong Zang and Joseph Irudayaraj and Tao, {W. Andy} and Peter Hollenhorst and Roberto Pili",
year = "2017",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-17-0899",
language = "English (US)",
volume = "77",
pages = "6651--6666",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming

AU - Adelaiye-Ogala, Remi

AU - Budka, Justin

AU - Damayanti, Nur P.

AU - Arrington, Justine

AU - Ferris, Mary

AU - Hsu, Chuan Chih

AU - Chintala, Sreenivasulu

AU - Orillion, Ashley

AU - Miles, Kiersten Marie

AU - Shen, Li

AU - Elbanna, May

AU - Ciamporcero, Eric

AU - Arisa, Sreevani

AU - Pettazzoni, Piergiorgio

AU - Draetta, Giulio F.

AU - Seshadri, Mukund

AU - Hancock, Bradley

AU - Radovich, Milan

AU - Kota, Janaiah

AU - Buck, Michael

AU - Keilhack, Heike

AU - McCarthy, Brian P.

AU - Persohn, Scott A.

AU - Territo, Paul

AU - Zang, Yong

AU - Irudayaraj, Joseph

AU - Tao, W. Andy

AU - Hollenhorst, Peter

AU - Pili, Roberto

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC). Recent reports suggest that drug resistance is driven by tumor adaptation via epigenetic mechanisms that activate alternative survival pathways. The histone methyl transferase EZH2 is frequently altered in many cancers, including ccRCC. To evaluate its role in ccRCC resistance to RTKi, we established and characterized a spontaneously metastatic, patient-derived xenograft model that is intrinsically resistant to the RTKi sunitinib, but not to the VEGF therapeutic antibody bevacizumab. Sunitinib maintained its antiangiogenic and antimetastatic activity but lost its direct antitumor effects due to kinome reprogramming, which resulted in suppression of proapoptotic and cell-cycle–regulatory target genes. Modulating EZH2 expression or activity suppressed phosphorylation of certain RTKs, restoring the antitumor effects of sunitinib in models of acquired or intrinsically resistant ccRCC. Overall, our results highlight EZH2 as a rational target for therapeutic intervention in sunitinib-resistant ccRCC as well as a predictive marker for RTKi response in this disease.

AB - Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC). Recent reports suggest that drug resistance is driven by tumor adaptation via epigenetic mechanisms that activate alternative survival pathways. The histone methyl transferase EZH2 is frequently altered in many cancers, including ccRCC. To evaluate its role in ccRCC resistance to RTKi, we established and characterized a spontaneously metastatic, patient-derived xenograft model that is intrinsically resistant to the RTKi sunitinib, but not to the VEGF therapeutic antibody bevacizumab. Sunitinib maintained its antiangiogenic and antimetastatic activity but lost its direct antitumor effects due to kinome reprogramming, which resulted in suppression of proapoptotic and cell-cycle–regulatory target genes. Modulating EZH2 expression or activity suppressed phosphorylation of certain RTKs, restoring the antitumor effects of sunitinib in models of acquired or intrinsically resistant ccRCC. Overall, our results highlight EZH2 as a rational target for therapeutic intervention in sunitinib-resistant ccRCC as well as a predictive marker for RTKi response in this disease.

UR - http://www.scopus.com/inward/record.url?scp=85037704869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037704869&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-0899

DO - 10.1158/0008-5472.CAN-17-0899

M3 - Article

C2 - 28978636

AN - SCOPUS:85037704869

VL - 77

SP - 6651

EP - 6666

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -